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BACKGROUND: Hypertensive disorders of pregnancy (HDP) are multisystem disorders unique to 
human pregnancy. They are becoming the leading causes of maternal mortality worldwide, with the 
majority of deaths occurring in low income countries. However, little is known about the predictors of 
maternal mortality in women with HDP.  
METHODS: A retrospective cohort study was conducted between 2008 and 2013 in three university 
teaching hospitals among 1015 women admitted with a diagnosis of HDP. Statistically significant 
associations were assessed by the hazard ratio (HR) with 95% confidence using the Cox proportional 
hazards model and by the Log Rank test using the Kaplan-Meier survival analyses.  
RESULTS: There were 51(5%) maternal deaths and the majority died after they developed eclampsia. 
The median delay in arrival among the deaths was longer than the survivors. The multivariate survival 
analyses showed an increased risk of maternal mortality among women with eclampsia (HR=8.4), no 
antenatal care (HR=2.3), being grand multiparous (HR=2.8), having low diastolic blood pressure 
(HR=4.5), high creatinine level (HR=9.9), use of diazepam as anticonvulsant (HR=2.7) and untreated 
with antihypertensive drug (HR=4.2).  
CONCLUSIONS: The case fatality rate of HDP was among the highest in the world and a delay in 
initiation of treatment because of delay in health care-seeking contributed to the majority of maternal 
deaths.  
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Hypertensive disorder of pregnancy is commonly 
used to describe a broad spectrum of hypertension 
related diseases during pregnancy. These disorders 
can appear for the first time during pregnancy 
(preeclampsia, eclampsia, gestational 
hypertension, HELLP syndrome) or may result 
from already established medical disorders 
(chronic hypertension, renal disease, systemic 
disease) (1). In general, hypertensive disorders of 
pregnancy (HDP) may complicate 5%-10% of 
pregnancies in the general population and are 
known to increase the risks of maternal and 
perinatal morbidity and mortality (2).  
A recent literature review has shown that the 
incidence of HDP is increasing mainly due to 
increasing obesity trend, and these disorders are 
becoming the leading causes of maternal mortality 
worldwide (3,4). An author estimated that HDP 
have contributed to 10% to 15% of direct maternal 
deaths globally (5). However, there is a significant 
variation in the proportion of maternal mortality 
due to these disorders between the low and high 
income countries. It was noted that the majority of 
maternal deaths associated with hypertensive 
disorders occur in the low-and middle-income 
countries (6).    
In South Africa, for instance, hypertensive 
disorders were the commonest direct causes of 
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maternal deaths; in some areas, these disorders 
contributed to 19%-32% of all maternal deaths (7, 
8). Similar studies in India and Pakistan revealed a 
high maternal mortality associated with HDP (9, 
10). Few hospital based studies in Ethiopia have 
also shown that hypertensive disorders are among 
the top three causes of maternal mortality (11, 12). 
Furthermore, a national survey in Ethiopia 
demonstrated that 11% of all maternal deaths and 
16% of direct maternal deaths occurred due to 
HDP and the cause-specific case fatality rate was 
3.6% (13).  
However, these studies were limited to 
describing the magnitude of maternal mortality 
due to HDP. Even in the international arena, 
literature on predictors of maternal mortality in 
women with HDP are scarce. Therefore, the 
purpose of the current study was to assess the 
predictors of maternal mortality in three teaching 
hospitals in Ethiopia among women diagnosed to 




Study design and setting: A retrospective cohort 
study was conducted from 2008 to 2013 in three 
university teaching hospitals in the Southern 
Regional State of Ethiopia (Hawassa referral 
hospital, Hosanna hospital and Yirgalem hospital). 
In these hospitals, a total of 30,750 babies was 
delivered during the study period. All women with 
HDP admitted to the study hospitals during the 
study period were included unless they were 
categorized as ineligible for this study (gave birth 
before 28 weeks of gestation, lost or incomplete 
data, or died on arrival). For each patient, the 
included data were from onset of HDP to the time 
end of treatment declared (mother discharged as 
cure or dead).  
 
Variables and data collection: Maternal 
mortality was taken as dependent or outcome 
variable. The independent variables were: 
maternal age, parity, gestational age, antenatal 
care, onset and type of HDP, severity symptoms, 
blood pressure, selected renal and liver function 
tests, types of medications and mode of delivery.  
Nine nurse (three for each hospital), who 
were working in the department of Obstetrics and 
Gynecology, were recruited and trained as data 
collectors. Since every woman with HDP was 
found registered in the delivery logbook, their card 
number documented in the delivery logbook was 
used as an initial entry to access their chart (where 
the detailed data is documented) in the hospital 
record office. Data collections were performed 
using a structured data collecting format prepared 
only for this purpose. The data collection format 
was designed to include all the relevant 
information starting from the onset of signs and 
symptoms of HDP to the time end date was 
declared.   
 
Data processing & analysis: Data were coded, 
entered, and analyzed using computer data 
analysis software program (SPSS version 20). 
Whisker and Box plotting was performed to assess 
the contribution of gestational age and delay in 
arrival to maternal mortality. We used Kaplan-
Meier survival analyses for cumulative mortality 
rates in relation to parity, type of HDP, onset of 
HDP and type of anticonvulsant drug. Cox 
proportional hazards regression model was used to 
estimate associations between selected predictor 
variables/covariates and maternal mortality taking 
the onset of HDP illness to death or discharge 
from the hospital as time period. A statistically 
significant association was considered when the 
hazard ratio (HR) 95% confidence interval did not 
include the number 1. Variables which did not 
show statistical significance in the univariate 
analysis were excluded in the multivariate 
analysis.  
 
Operational definitions: Pregnant or postpartum 
women were grouped as normotensive [systolic 
blood pressure (BP) <140 mmHg and diastolic 
BP<90 mmHg], mild to moderate hypertension 
(systolic BP≥140 mmHg and diastolic BP≥90 
mmHg) and severe hypertension (systolic BP≥160 
mmHg and diastolic BP≥110 mmHg).  
Presence of hypertension or severity 
symptoms with significant proteinuria was enough 
to diagnose preeclampsia. Eclampsia was defined 
as the occurrence of convulsion or coma not 
attributable to other causes. Presence of 
hypertension before the occurrence of pregnancy 
or that was diagnosed before 20 weeks of 
gestation was taken as chronic hypertension. 
Superimposed preeclampsia was diagnosed when 
a new onset or worsening of proteinuria and/or 
worsening of hypertension occurred during 
pregnancy in women with a known chronic 
hypertension. Gestational hypertension was 
defined as the development of an elevated blood 




pressure during the second half of pregnancy 
without proteinuria and severity symptoms. In this 
article, other HDP include all women with chronic 
hypertension, gestational hypertension and 
superimposed preeclampsia. 
Severity symptoms of HDP include headache, 
blurred vision, epigastric pain and vomiting. 
Proteinuria was considered as significant when the 
qualitative test (dipstick) revealed +2 and above or 
+1 if the specific gravity was <1.020. Creatinine 
level <1 and 1+ mg/dl and Serum glutamic-
oxaloacetic transaminase (SGOT) level raised by 
< or >2-fold from the base line were included in 
the analysis as proxy indicators for status of renal 
function and liver function, respectively. Platelet 
count was also dichotomized as < or 
>100,000/mm3. Degree of anemia was 
categorized as severe to moderate (< 10gm/dl), 
mild (10-11.9 gm/dl) and no anemia (12+gm/dl). 
 
 Ethical consideration: Ethical clearance was 
obtained from the Institutional Review Board of 
Hawassa University, College of Medicine and 
Health Sciences. Since the study was retrospective 
by design, written consent from patients was not 
required. Patient records were de-identified prior 
to data analysis. Furthermore, anonymity was 





The logbook review identified 1098 women 
registered as HDP. After excluding 83 ineligible 
cases that were diagnosed to have HDP (38 
patients chart lost, 36 with incomplete data, 6 
delivered before 28 weeks and 3 died on arrival), 
we analyzed data for 1015 women. The mean age 
of the included women was 25.8+5.2 years (range 
of 15-46 years). The distribution of HDP by type 
was: 612(60.3%) preeclampsia, 346(34.1%) 
eclampsia and 57(5.6%) other type of HDP 
(chronic hypertension, gestational hypertension 
and superimposed preeclampsia). Six hundred 
thirty-three (62.4%) of these women had antenatal 
care (ANC) in a health facility and 847(83.4%) 
presented with one or more of the severity 
symptoms of HDP (headache, blurred vision, 
epigastric pain and/or vomiting). Out of 60 women 
with systolic BP<140 mmHg, and out of 39 
women diastolic BP<90 mmHg, 62% and 64% 
were eclamptic mothers, respectively. A separate 
analysis presented the detail description of socio-
demographic and obstetric data of the included 
women.  
Of the total women included in this analysis, 
51 died in the hospital after initiation of treatment, 
making the case fatality rate of HDP 5%. The 
majority of maternal deaths (78.4%), however, 
occurred in women with eclampsia. As a result, 
the case fatality rates of eclampsia, preeclampsia 
and other type of HDP were 11.6%, 1.1% and 
7.0%, respectively.  
Figure 1 shows the relation of maternal 
deaths with the gestational age as stratified by type 
of HDP. In women with eclampsia, the median 
gestational ages of deaths and survivors were 
equivalent (38 weeks each). However, it should be 
noted that several outliers of survivors with low 
gestational age were excluded from this Figure. 
The median gestational ages for preeclampsia and 
other type of HDP were found to be lower in 
maternal deaths than the survivors, 30 vs 37 weeks 
and 32 vs 37 weeks, respectively. The interquartile 
range (IQR) of the gestational age for maternal 
deaths due to preeclampsia and other type of HDP 
were also 30-34 and 28-34 weeks, respectively.  
 The relation of maternal deaths with delay in 
arrival as stratified by type of HDP is presented in 
Figure 2A-D. In the overall assessment, the 
median delays in arrival among the maternal 
deaths and survivors were 24 (IQR 12-48) and 48 
(IQR 12-96) hours, respectively. The range of 
delay was also 4-720 hours for deaths and 2-1440 
hours for survivors. However, when the data were 
stratified by type of HDP, a marked delay was 










Figure 1: The relation of maternal death with gestational age at the onset of the illness in different type of 
hypertensive disorders of pregnancy (HDP), Ethiopia, 2008-2013 (Outliers were excluded) 
 
Specifically, the median delay in hours among 
maternal deaths was twice of the survivors in 
eclamptic women (24 vs 12), and about two and 
half-fold longer than the survivors in women with 
preeclampsia (168 vs 72) or other type of HDP 
(120 vs 48). Of interest, the delays in all maternal 
deaths among the preeclamptic and the other HDP 
group were not beyond the median value.   
 
 
Figure 2 A-D: The maternal outcome on discharge in relation to delay in arrival as stratified by type of hypertensive 
disorders of pregnancy (HDP), Ethiopia, 2008-2013 (Outliers were excluded) 
 
Table 1 shows the Cox regression survival 
analysis of maternal deaths with selected 
demographic and clinical findings. In the 
univariate analysis, maternal death was strongly 
associated with grand multiparity (Crude Hazard 
ratio = 3.6), lack of ANC (CHR=3.5), eclampsia 
(CHR=11.3), other type of HDP (CHR=6.5), 
intrapartum (CHR=2.6) and postpartum onset of 




HDP (CHR=3.5), ever highest systolic blood 
pressure (BP)<140 mmHg (CHR=2.8), and ever 
highest diastolic BP<90 mmHg in the current 
illness (CHR=4.3). The univariate model did not 
show association of maternal mortality with 
previous history of HDP, diabetes mellitus and 
renal disease. Helou G, Alassas N, 
In the multivariate analysis, grand 
multiparous women had 2.8 times increased risk 
of mortality as compared with multiparous and 
primigravid women. Similarly, those women with 
no ANC were 2.3 times more likely to die than 
their counterparts. The risk of dying in eclamptic 
women had also increased by 8.4-fold as 
compared to preeclamptic women. Women having 
highest diastolic BP<90 mmHg were also at 
higher risk of death than women with severe 
diastolic hypertension (AHR=4.5). Onset of HDP 
and highest systolic BP<140mmHg in the 
multivariate analysis, and age, severity symptoms 
and gestational age in the univariate analysis did 
not show association with maternal death.   
 
 
Table 1: Cox regression survival analysis of women with hypertensive disorders of pregnancy (HDP) in relation to 










HR (95% CI) 
Adjusted 
HR (95% CI) 
Age in years: 
     15 – 19 
     20 – 34 










1.9(0.74 - 4.78) 
1 
1.3 (0.51 - 3.24) 
 
Parity:  
   Primigravida 
   Multipara (I – IV) 











1.0 (0.52 – 1.88) 
3.5 (1.69 – 7.10)‡ 
 
1 
0.8 (0.38 – 1.84) 
2.8 (1.13 – 6.78)¥ 
Gestational age (weeks)* 
   Very preterm (< 34) 
   Preterm (34 – 36) 










1.4 (0.56 – 3.39) 




       Yes 









3.5 (1.95 -  6.43)† 
 
1 
2.3 (1.19 - 4.38)¥ 
Type of HDP: 
     Preeclampsia 
     Eclampsia 











11.3(1.85 – 22.99)† 
6.5(5.00 – 25.52)‡ 
 
1 
8.4(3.48 – 20.15)† 
5.0(1.35 – 18.64)‡ 
Onset of HDP: 
     Antepartum or before 
     Intrapartum 











2.6 (1.33 - 5.05)‡ 
3.5 (1.71 - 7.26)‡ 
 
1 
1.8(0.86 - 3.72) 
1.0(0.40 - 2.57) 
Severity symptoms: 
     Yes (one or more) 












Highest systolic BP:   
     < 140 mmHg   
      140 – 159 










2.8 (1.17 – 6.63)¥ 
1.1 (0.55 – 2.07) 
1 
 
0.8 (0.21 – 3.06) 
0.7 (0.33 – 1.67) 
1 
Highest diastolic BP:   
     < 90 mmHg   
      90 – 109 










4.3 (1.72 – 10.49)‡ 
0.8 (0.44 – 1.51) 
1 
 
4.5 (1.11 – 18.65) ¥ 
1.0 (0.47 – 2.12) 
1 
¥ P < 0.05; ‡ P = 0.001; † p < 0.0001. HR = Hazard ratio. BP = Blood pressure. * Gestational age at the onset of the 
HDP. 





The association of maternal deaths with selected 
laboratory findings and treatment modalities is 
presented in Table 2. In the univariate analysis, 
some of the laboratory findings which showed a 
statistically significant association with maternal 
death were hemoglobin <12gm/dl (CHR=2.3 - 
3.7), platelet count <100,000/mm3 (CHR=7.0), 
creatinine ≥1mg/dl (CHR=3.7), and SGOT ≥ 2-
fold raised (CHR=2.7). Proteinuria was not 
associated with maternal death. 
  
 
Table 2: Cox regression survival analysis of women with hypertensive disorders of pregnancy (HDP) in relation to 










HR (95% CI) 
Adjusted 
HR (95% CI) 
     
Hemoglobin level (gm/dl): 
        <10.0 
       10-11.9 










3.7(1.82 - 7.35)† 
2.3(1.17 - 4.57)¥ 
1 
 
1.6 (0.38 - 6.69) 
2.1 (0.64 - 6.86) 
1 
Platelet count in mm3: 
        < 100 








7.0 (3.35 - 14.51)† 
1 
 
2.3(0.73 – 7.18) 
1 
Proteinuria (qualitative): 
        Insignificant 









1.3 (0.66 – 2.59) 
 
Highest creatinine (gm/dl): 
                  < 1.0 














               < 2-fold raised 









2.7 (1.09 – 6.64)¥ 
 
1 
1.7 (0.58 – 5.24) 
Antihypertensive drug given:      
Yes 









2.5 (1.39 – 4.51)‡ 
 
1 
4.2(1.46 - 11.91)‡ 
Anticonvulsant given:  
              MgSo4 









3.4(1.86 – 6.04)† 
 
1 
2.7 (1.1 – 8.08)¥ 
Mode of delivery: 
         Vaginal 








2.4 (1.22 -  4.57)¥ 
1 
 
2.8(0.70 - 10.90) 
1 
¥ P < 0.05; ‡ P = 0.001; † p < 0.0001. HR = Hazard ratio. SGOT = Serum glutamic-oxaloacetic transaminase 
 
Women who were not given any antihypertensive 
drug were at higher risk for death (CHR=2.5). 
Diazepam as anticonvulsant (CHR=3.4) and 
vaginal delivery of any type (CHR = 2.4) had also 
increased the risks of maternal death. In the 
multivariate analysis, however, only high 
creatinine value (AHR=9.9), failure to take 
antihypertensive drug (AHR=4.2) and use of 
diazepam as anticonvulsant (AHR=2.7) were 
strong and independent predictors of maternal 
death.      
In general, the majority of maternal deaths 
occurred before 48 hours (65%), and nearly half 
occurred before 24 hours (47%) of onset of illness. 
However, there were 10(20%) maternal deaths 
that occurred between 4 and 31 days of onset of 
illness.  
As a complement to the findings in Table 1 
and 2, Kaplan-Meier survival analyses of maternal 
mortality were performed taking the period of 
onset of HDP to discharge or death as time frame; 
and parity, onset of HDP, type of HDP and type of 
anticonvulsant as independent factors. As the time 
of hypertensive illness increased, the survival of 
grand multiparous women was lesser than 
multiparous and primigravid women (Log Rank: 
P=0.001). Similarly, the survival of eclamptic 
mothers was lower than that of mothers with 




preeclampsia or other type of HDP as the duration 
of illness advanced (Log Rank: P<0.0001). In 
terms of timing, women with antepartum onset of 
HDP had better survival than intrapartum and 
postpartum onset of HDP (Log Rank: P<0.0001). 
Hypertensive mothers who were given magnesium 




Figure 3 A-D. Survival of women with hypertensive disorders of pregnancy (HDP) across the course of illness as 




The overall maternal mortality of HDP in this 
study was similar to a study report from Pakistan 
(5.5%) (10), but higher than other studies reports 
(13-15). Specifically, the contribution of 
eclampsia for the overall maternal deaths (78%) 
was more than 3-fold higher than a report from a 
tertiary hospital in Ghana (24%) (14). The 
proportion of eclampsia related maternal mortality 
reports from a population based study in South 
Africa (57%) (16) and from a tertiary hospital 
based study in India (67%) (15) were also 
somehow lower than our report. Similar to our 
finding (11.6%), high case fatality rates of 
eclampsia were reported from Tanzania (7.9%) 
and Nigeria (10.7%) (17, 18). However, our 
finding was less than the report from Northern 
Nigeria (23.2%) (19) by half. 
The high maternal mortality among eclamptic 
mothers in this study was probably the result of 
the big delay in health care-seeking before (lack of 
ANC) and after the onset of the illness. As it was 
noted in the Whisker and Box plot graph, the 
median time delay before arrival among deaths 
was longer than that of the survivors in all types of 
HDP. Furthermore, it was noted that some 
mothers developed eclampsia in normotensive and 
symptom free-state, which was also reported in 





several other studies (20-22). However, being 
eclampsia nearly one-third of the included cases 
(34%) and the very high maternal mortality in this 
group of women may still indicate the significant 
delay in initiating anticonvulsant prophylaxis and 
antihypertensive drugs, among other lifesaving 
interventions.  
Consistent with the finding of a previous 
study (14), most of the maternal deaths occurred 
within the first 24 hours of admission, which may 
further strengthen the contribution of delay in 
initiating treatment or the ineffectiveness of 
treatment modalities. Specifically, it is known that 
eclampsia cases are likely to deteriorate fast unless 
further convulsions are aborted as early as 
possible. In other words, we surmise that those 
mothers who were died critically ill at admission 
or there were further delays in initiating treatment 
modalities after admission, for which we were not 
able to get data on the time interval between 
arrival and initiation of treatment. Previous 
authors also noted that the most important factor 
contributing to high maternal mortality due to 
HDP in developing countries is late arrival to 
hospital in irreversible stage of disease (23). 
On the other hand, as the multivariate and 
survival analyses showed, the use of diazepam as 
anticonvulsant probably contributed much to the 
high maternal mortality due to eclampsia. This is 
because, as authors observed, before the 
magnesium sulphate was instituted in 2010 to the 
study hospitals as anticonvulsant for women with 
HDP, diazepam was the sole anticonvulsant agent. 
The ineffectiveness of diazepam as anticonvulsant 
for hypertensive pregnant women has also been 
shown in several other studies (24-26).  
The multivariate analyses have also shown 
more than 2-fold increased risk of maternal 
mortality among women with no ANC, being 
grand multipara, having low diastolic BP, high 
creatinine level and untreated with 
antihypertensive drug. The association of lack of 
ANC follow up with high maternal mortality was 
also noted in several other studies (2-4, 24). 
Similarly, other studies showed the strong 
association of maternal mortality with grand 
multiparity (1-3), probably due to their additional 
susceptibility to other obstetric complications (1).  
The independent association of high 
creatinine level with increased risk of maternal 
mortality may indicate the severity of the HDP. 
However, the strong association of maternal 
mortality with low blood pressure, failure to get 
antihypertensive drugs and intrapartum and 
antepartum onset of HDP after admission to one of 
the study hospitals seem to show that one factor 
was interrelated with another one.  
Since the protocol (27) for initiation of 
antihypertensive drug require the finding of blood 
pressure in the severe state (>160/110 mmHg), 
which is also the recommendation of other 
literatures (28, 29), women in normotensive or 
mild to moderate hypertension state were unlikely 
to get antihypertensive drug. Similarly, the 
majority (56%) of women who died with 
intrapartum and antepartum onset of HDP were 
not eligible for antihypertensive drug.       
Nevertheless, the association of maternal 
mortality with low blood pressure needs to be 
interpreted very cautiously. Firstly, the majority of 
women with normal blood pressure during their 
hospital stay were eclamptic, who have probably 
already developed further complications including 
multiple organ failure. This was partly evidenced 
by the strong association of maternal mortality 
with low platelet count, severe to moderate 
anemia, elevated creatinine and liver enzyme 
level. Secondly, because of the exactly unknown 
nature of these diseases course (30, 31), some 
women might still have low blood pressure record 
while the systemic effect of the disease was in the 
worst state.       
Otherwise, the increased maternal mortality 
observed in women with early onset of HDP 
among preeclamptic and other type of HDP was 
not verified by the Cox proportional hazards 
models and Kaplan Meier survival analyses. This 
observation needs further investigation. Similarly, 
the observed increased risk of maternal mortality 
in the univariate analysis among women who gave 
birth vaginally needs to be interpreted very 
cautiously. Caesarean delivery is known to result 
in expeditious delivery and probably has reduced 
the risk of HDP related mortality. However, till a 
randomized clinical trial demonstrates the 
significance of caesarean delivery to reduce 
maternal mortality, the current evidence should be 
taken as inadequate.      
This study was not without limitation. The 
retrospective nature of the study design could not 
give us room to find some data on social and 
service related factors. As a result, we were not 




able to control all potential determinants of 
maternal mortality in women with HDP. 
Furthermore, since our data relied on record 
review, which might not be accurately recorded, 
the comparisons made on temporal relationship 
between exposed and non-exposed may be biased. 
Because of physiologic drop of blood pressure in 
the second trimester and decreased blood urea 
nitrogen and creatinine (32), some of the women 
who were diagnosed to have new onset 
hypertension probably had preconception 
hypertension.      
In conclusion, the case fatality rate of HDP 
was among the highest in the world, and the 
analysis indicated that the majority of maternal 
deaths were linked to delay in providing obstetric 
care because of lack of antenatal care, delay in 
arrival, or delay in initiation of appropriate 
treatment. Therefore, health promotion should be 
provided to pregnant women focusing on 
awareness creation on the importance of 
antepartum and intrapartum care, and risk 
preparedness to seek health care when they 
experience HDP severity symptoms. Furthermore, 
the strong association of maternal mortality with 
low blood pressure is an area of investigation to 
redefine the threshold for initiation of 
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